Advertisement

New Device Strategies in the Management of Acute Coronary Syndromes

  • Mukesh Goel
  • Anthony M. Sparano
  • John Moynihan
  • Michael Kelley
  • C. Michael Gibson
Chapter
Part of the Contemporary Cardiology book series (CONCARD)

Abstract

Conventional percutaneous transluminal coronary angioplasty (PTCA) has been used to treat patients with coronary artery disease for over a decade now, but it is limited by a 5% rate of death or acute myocardial infarction (MI), a 2–3% rate of coronary artery bypass graft (CABG) surgery, and a 30–50% risk of restenosis (1–4). These limitations are partly due to coronary artery dissection with the attendant risk of acute vessel closure, as well as the late restenotic response to injury following the uncontrolled plaque disruption and vessel stretching associated with balloon dilation.

Keywords

Coronary Artery Bypass Graft Coronary Artery Bypass Graft Surgery Coronary Stenting Rotational Atherectomy Intracoronary Stenting 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Detre K, Holobkov R, Kelsey S. Percutaneous transluminal coronary angioplasty in 1985–1986 and 1977–1981. N Engl J Med 1988; 318: 265–270.PubMedCrossRefGoogle Scholar
  2. 2.
    Serruys PW, de Jaegere P, Kiemeneji F, Macaya C, Rutsch W, Heyndrickx G, et al. A comparison of balloon-expandable stent implantation with balloon angioplasty in patients with coronary artery disease. Benestent Study Group. N Engl J Med 1994;331:489–495.CrossRefGoogle Scholar
  3. 3.
    Fischman DL, Leon MB, Bairn DS, Schatz RA, Savage MP, Penn I, et al. A randomized comparison of coronary stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent Restenosis Study Investigators. N Engl J Med 1994; 331: 496–501.PubMedCrossRefGoogle Scholar
  4. 4.
    Nobuyoshi M, Kimura T, Nosaka H, Mioka S, Ueno K, Yokoi H, et al. Restenosis after successful percutaneous transluminal coronary angioplasty: serial angiographic follow up of 229 patients. J Am Coll Cardiol 1988; 12: 616–23.PubMedCrossRefGoogle Scholar
  5. 5.
    The EPIC Investigators. Use of monoclonal antibody directed against the platelet glycoprotein Ilb/IIIa receptor in high risk angioplasty. N Engl J Med 1994; 3309: 956–961.Google Scholar
  6. 6.
    Topol EJ, Ferguson JJ, Weisman HF, Tcheng JE, Ellis SG, Kleiman NS, et al. Long-term protection from myocardial ischemic events in a randomized trial of brief integrin ß3 blockade with percutaneous coronary intervention. JAMA 1997; 278: 479–484.PubMedCrossRefGoogle Scholar
  7. 7.
    Lincoff AM, for the EPILOG Investigators. Platelet glycoprotein IIbIIla receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med 1997; 336: 1689–1696.CrossRefGoogle Scholar
  8. 8.
    The IMPACT Investigators. Randomized placebo controlled trial of the effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II. Lancet 1997; 349: 1422–1428.CrossRefGoogle Scholar
  9. 9.
    King III SB, for the RESTORE Investigators. Effects of platelet glycoprotein IIB/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. Circulation 1997; 96: 1445–1453.CrossRefGoogle Scholar
  10. 10.
    Ryan TJ, Bauman WB, Kennedy JW, Kereiakes DJ, King III SB, McCallister BD, et al. Guidelines for percutaneous transluminal coronary angioplasty: a report of the ACC/AHA task force. J Am Coll Cardiol 1993; 22: 2033.Google Scholar
  11. 11.
    Rozenman Y, Gilon D, Welber S, Sapoznikov D, Gotsman MS. Clinical and angiographie predictors of immediate recoil after successful coronary angioplasty and relation to late restenosis. Am J Cardiol 1993; 72: 1020.PubMedCrossRefGoogle Scholar
  12. 12.
    Kuntz RE, Gibson CM, Nobuyoshi M, Bairn DS. Generalized model of restenosis after conventional balloon angioplasty, stenting and directional atherectomy. J Am Coll Cardiol 1993; 21: 15–25.PubMedCrossRefGoogle Scholar
  13. 13.
    Roubin GS, Douglas JS, King SB, Lin SF, Hutchison N, Thomas RG, et al. Influence of balloon size on initial success, acute complications, and restenosis after percutaneous transluminal coronary angioplasty: a prospective randomized study. Circulation 1988; 78: 557–565.PubMedCrossRefGoogle Scholar
  14. 14.
    Holmes DR, Mehta S, George CJ, Margolis JR, Leon MB, Isner JM, et al. Excimer laser coronary angioplasty: the New Approaches to Coronary Intervention (NACI) Experience. Am J Cardiol 1997; 80: 99K–105K.PubMedCrossRefGoogle Scholar
  15. 15.
    Vandormael M, Reifert N, Preusler W, Schwarz F, Storger H, Hofmann M, et al. Six months follow-up results following excimer laser angioplasty, rotational atherectomy and balloon angioplasty for complex coronary lesions: ERBAC Study. Circulation 1994; 90 (Suppl): I-213.Google Scholar
  16. 16.
    Deckelbaum LI, Natarajan MK, Bittl JA, Rohlfs K, Scott J, Chisholm R, et al. Effect of intracoronary saline infusion on dissection during excimer laser coronary angioplasty: a randomized trial. The percutaneous excimer laser coronary angioplasty (PELCA) investigators. J Am Coll Cardiol 1995; 26: 1264–1269.PubMedCrossRefGoogle Scholar
  17. 17.
    Safian RD, Gelbfish JS, Erny RE, Schnitt Si, Schmidt DA, Baim DS. Coronary atherectomy. Clinical, angiographic, and histological findings and observations regarding potential mechanisms. Circulation 1990; 82: 69–79.PubMedCrossRefGoogle Scholar
  18. 18.
    Topol EJ, Leya F, Pinkerton CA, Whitlow PL, Hofling B, Simonton CA, et al. A comparison of directional atherectomy with coronary angioplasty in patients with coronary artery disease. The CAVEAT Study Group. N Engl J Med 1993; 329: 221–227.PubMedCrossRefGoogle Scholar
  19. 19.
    Holmes DR, Topol EJ, Califf RM, Berdan LG, Leya F, Berger PB, et al. A Multicenter, randomized trial of coronary angioplasty versus directional atherectomy for patients with saphenous vein graft lesions: CAVEAT-II Investigators. Circulation 1995; 91: 1966–1974.PubMedCrossRefGoogle Scholar
  20. 20.
    Adelman AG, Cohen EA, Kimball BP, Bonan R, Ricci DR, Webb JG, et al. A comparison of directional atherectomy with balloon angioplasty for lesions of the left anterior descending artery. N Engl J Med 1993; 329: 228.PubMedCrossRefGoogle Scholar
  21. 21.
    Elliott JM, Berdan LJ, Holmes DR, Isner JM, King III SB, Keeler GP, et al. One-year follow-up in the coronary angioplasty versus excisional atherectomy trial (CAVEAT-I). Circulation 1995; 91: 2158.Google Scholar
  22. 22.
    Lincoff A, Keeler G, Debowey D, Topol E. Is clinical site variability an important determinant of outcome following percutaneous revascularization with new technology? Insights from CAVEAT. Circulation 1993; 88 (Suppl I); I-653.Google Scholar
  23. 23.
    Baim DS, Cutlip DE, Sharma SK, Kalon KL, Fortuna R, Schreiber TL, et al. Final results of the balloon versus optimal atherectomy trial (BOAT). Circulation 1998; 97: 322–331.PubMedCrossRefGoogle Scholar
  24. 24.
    Leon M, Kuntz R, Popma J, Simonton C, Hinohara T, Mintz G, Bersin R, et al. Acute angiographic, intravascular ultrasound and clinical results of directional atherectomy in the optimal atherectomy restenosis study. J Am Coll Cardiol 1995; 25: 137A.Google Scholar
  25. 25.
    Zhou YF, Leon MB, Waclawiw MA. Association between prior cytomegalovirus infection and the risk of restenosis after coronary atherectomy. N Engl J Med 1996; 335: 624–627.PubMedCrossRefGoogle Scholar
  26. 26.
    Kovach JA, Mintz GS, Pichard AD, Kent KM, Popma JJ, Satler LF, et al. Sequential intravascular ultrasound characterization of the mechanisms of rotational atherectomy and adjunct balloon angioplasty. J Am Coll Cardiol 1993; 22: 1024.PubMedCrossRefGoogle Scholar
  27. 27.
    Ellis SG, Popma JJ, Buchbinder M, Franco I, Leon MB, Kent KM, et al. Relation of clinical presentation, stenosis morphology, and operator technique to the procedural results of rotational atherectomy and rotational atherectomy facilitated angioplasty. Circulation 1994; 89: 882–892.PubMedCrossRefGoogle Scholar
  28. 28.
    Warth DC, Leon MB, O’Neill W, Zacca N, Polissar N, Buchbinder M. Rotational atherectomy multicenter registry: acute results, complications and six month angiographic follow-up in 709 patients. J Am Coll Cardiol 1994; 24: 641.PubMedCrossRefGoogle Scholar
  29. 29.
    Dietz UR, Erbel R. Angiographic and histologic findings in high frequency rotational ablation in coronary arteries in vitro. Zeitschr Kardiol 1991; 80: 222–229.Google Scholar
  30. 30.
    Borrione M, Hall P, Almagor Y, Maiello L, Khlat B, Finci L, et al. Treatment of simple and complex coronary stenosis using rotational ablation followed by low-pressure balloon angioplasty. Cathet Cardiovasc Diagn 1993; 30: 131–137.PubMedCrossRefGoogle Scholar
  31. 31.
    Gilmore PS, Bass TA, Conetta DA, Percy RF, Chami YG, Kircher BJ, et al. Single site experience with high-speed coronary rotational atherectomy. Clin Cardiol 1993; 16: 311–316.PubMedCrossRefGoogle Scholar
  32. 32.
    Guerin Y, Rahal S, Desnos M, Funck F, Fernandez F, Sahnoun M, et al. Coronary angioplasty combining rotational atherectomy and balloon dilatation. Results in 67 complex stenoses. Arch Mal Coeur 1993; 86: 1535–1541.PubMedGoogle Scholar
  33. 33.
    Stertzer SH, Rosenblum J, Shaw RE, Sugeng I, Hidalgo B, Ryan C, et al. Coronary rotational ablation: initial experience in 302 procedures. J Am Coll Cardiol 1993; 21: 287–295.PubMedCrossRefGoogle Scholar
  34. 34.
    Safian RD, Niazi KA, Strzelecki M, Lichtenberg A, May MA, Juran N, et al. Detailed angiographic analysis of high-speed mechanical rotational atherectomy in human coronary arteries. Circulation 1993; 88: 961–968.PubMedCrossRefGoogle Scholar
  35. 35.
    MacIsaac AI, Bass TA, Buchbinder M, Cowley MJ, Leon MB, Warth DC, et al. High speed rotational atherectomy: outcome in calcified and non-calcified coronary artery lesions. J Am Coll Cardiol 1995; 26: 531–536.CrossRefGoogle Scholar
  36. 36.
    Stertzer SH, Pomerantsev EV, Fitzgerald P7, Shaw RE, Walton AS, Singer AH, et al. Effects of technique modification on immediate results of high speed rotational atherectomy in 710 procedures on 656 patients. Cathet Cardiovasc Diagn 1995; 304–310.Google Scholar
  37. 37.
    Sketch MH, Davidson CJ, Yeh W, Margolis JR, Matthews RV, Moses JW, et al. Predictors of acute and long-term outcome with transluminal extraction catheter atherectomy: the new approaches to coronary intervention (NACI) registry. Am J Cardiol 1997; 80: 68K–77K.PubMedCrossRefGoogle Scholar
  38. 38.
    Gaspardone A, Versaci F, Tomai F, DeFazio A, Colantuano G, Iamele M, et al. Coronary angioplasty versus primary stent placement for isolated proximal left anterior descending artery stenosis. J Am Coll Cardiol 1996; 27 (Suppl A): 252A.CrossRefGoogle Scholar
  39. 39.
    Douglas JS, Savage MP, Bailey SR, Pepine CJ, Werner JA, Overlie PA, et al. Randomized trial of coronary stent and balloon angioplasty in the treatment of saphenous vein graft stenoses. J Am Coll Cardiol 1996; 27: 178A.Google Scholar
  40. 40.
    Sirnes PA, Golf S, Myreng Y, Mo/Istad P, Albertson P, Emanuelsson H, et al. Stenting in chronic coronary occlusions (SICCO): a multicenter randomized controlled study. J Am Coll Cardiol 1996; 27: 139A.Google Scholar
  41. 41.
    Thomas M, Hancock J, Holmberg S, Wainwright R, Jewitt D. Coronary stenting following successful angioplasty for total occlusions: preliminary results of a randomized trial. J Am Coll Cardiol 1996; 27: 153A.Google Scholar
  42. 42.
    Erbel R, Haude M, Hopp HW, Macaya C, Nobuyoshi M, Probst P, et al. Restenosis Stent Study: randomized trial comparing stenting and balloon angioplasty for treatment of restenosis after balloon angioplasty. J Am Coll Cardiol 1996; 27: 139A.Google Scholar
  43. 43.
    Kuntz RE, Piana R, Pomerantz RM, Carrozza J, Fishman R, Mansour M, et al. Changing incidence and management of abrupt closure following coronary intervention in the new device era. Cathet Cardiovasc Diagn 1992; 27: 183–90.PubMedCrossRefGoogle Scholar
  44. 44.
    Webb JG, Dodek AA, Allard M, Carere R, Marsh I. “Salvage atherectomy” for discrete arterial dissections resulting from balloon angioplasty. Can J Cardiol 1992; 8: 481–486.PubMedGoogle Scholar
  45. 45.
    Schieman G, Cohen BM, Kozina J, Erickson JS, Podolin RA, Peterson KL, et al. Intracoronary urkinase for intracoronary thrombus accumulation complicating percutaneous transluminal coronary angioplasty in acute coronary syndromes. Circulation 1990; 82: 2052–2060.PubMedCrossRefGoogle Scholar
  46. 46.
    Detre KM, Holmes DR, Holubkov, Cowley MJ, Bourassa MG, Faxon DP, et al. Incidence and consequences of periprocedural occlusion. The 1985–86 National Heart, Lung and Blood Institute percutaneous transluminal coronary angioplasty Registry. Circulation 1990; 82: 739–750.PubMedCrossRefGoogle Scholar
  47. 47.
    Schomig A, Kastrati A, Mudra H, Blasini R, Schuhlen H, Klauss V, et al. Four year experience with Palmaz-Schatz stenting in coronary angioplasty complicated by dissection with threatened or present vessel closure. Circulation 1994; 90: 2716–2724.PubMedCrossRefGoogle Scholar
  48. 48.
    Carroza JP, George CJ, Curry C. Palmaz-Schatz stenting for non-elective indications: report from the New Approaches to Coronary Intervention (NACI) registry. Circulation 1995; 92 (suppl I): I-86.Google Scholar
  49. 49.
    George BS, Voorhees WD, Roubin GS, Fearnot NE, Pinkerton CA, Raizner AE, et al. Multicenter investigation of coronary stenting to treat acute or threatened closure after percutaneous transluminal coronary angioplasty: clinical and angiographic outcomes. J Am Coll Cardiol 1993; 22: 135–143.PubMedCrossRefGoogle Scholar
  50. 50.
    Vrolix M, Piessens J. Usefulness of the Wiktor stent for treatment of threatened or acute closure complicating coronary angioplasty. The European Wiktor Stent Study Group. Am J Cardiol 1994; 73: 737–741.PubMedGoogle Scholar
  51. 51.
    Cohen EA, Schwartz L. Coronary stenting: indications and cost implications. Prog Cardiovasc Dis 1996; 30: 83–110.CrossRefGoogle Scholar
  52. 52.
    Zampieri P, Colombo A, Almagor Y, Maiello L, Finci L. Results of coronary stenting of ostial lesions. Am J Cardiol 1994; 73: 901–903.PubMedCrossRefGoogle Scholar
  53. 53.
    Fajadet J, Brunel P, Jordan C, Cassagneau B, Marco J. Is stenting of left main coronary artery a reasonable procedure. Circulation 1995; 92 (Suppl I): I-74 (abstract).Google Scholar
  54. 54.
    Colombo A, Maiello L, Itoh A, Hall P, DiMario C, Blengino S, et al. Coronary stenting of bifurcation lesions: Immediate and follow-up results. J Am Coll Cardiol 1996; 27 (Suppl A): 277A (abstract).CrossRefGoogle Scholar
  55. 55.
    Mak KH, Belli G, Ellis SG, Moliterno DJ. Subacute stent thrombosis evolving issues and current concepts. J Am Coll Cardiol 1996; 27: 494–503.PubMedCrossRefGoogle Scholar
  56. 56.
    Bittl JA. Subacute stent occlusion: thrombus horribilis. J Am Coll Cardiol 1996; 28: 368–370.PubMedCrossRefGoogle Scholar
  57. 57.
    Mudra H, Klauss V, Blasini R, Kroetz M, Rieber J, Regar E, et al. Ultrasound guidance of PalmazSchatz intracoronary stenting with a combined intravascular ultrasound balloon catheter. Circulation 1994; 90: 1252.PubMedCrossRefGoogle Scholar
  58. 58.
    Colombo A, Hall P, Nakamura S, Almagor Y, Maiello L, et al. Intracoronary stenting without anticoagulation accomplished with intravascular ultrasound guidance. Circulation 1995; 91: 1676–1688.PubMedCrossRefGoogle Scholar
  59. 59.
    Nakamura S, Hall P, Gaglione A, Tiecco F, DiMaggio M, Maiello L, et al. High pressure assisted coronary stent implantation accomplished without intravascular ultrasound guidance and subsequent anti-coagulation. J Am Coll Cardiol 1997; 29: 21–27.PubMedCrossRefGoogle Scholar
  60. 60.
    Walter H, Neumann FJ, Richardt G, Alt E, Schmitt C, Blasini R, et al. Antiplatelet vs. anticoagulation treatment after intracoronary Palmaz-Schatz stent placement in acute myocardial infarction. A prospective randomized trial. J Am Coll Cardiol 1996; 27: 279A.Google Scholar
  61. 61.
    Leon MB, Baim DS, Gordon P, Giambartolomei A, Williams DO, Diver DJ, et al. Clinical and angiographic results from the stent anticoagulation regimen study (STARS). Circulation 1996; 94: 1–685.CrossRefGoogle Scholar
  62. 62.
    Alexander W. Low restenosis with aspirin only after stenting. No difference in stent designs. Int Med World Rep Dec 1997; 10.Google Scholar
  63. 63.
    Jordan C, Carvalho H, Fajadet J, Cassagneau B, Robert G, Marco J. Reduction of acute thrombosis rate after coronary stenting using a new anticoagulant protocol. Circulation 1994; 90: I-125.Google Scholar
  64. 64.
    Wong SC, Popma J, Mintz G, Pichard A, Kent K, Satler L, et al. Preliminary results from the Reduced Anticoagulation in Saphenous vein grafts Stent Trial (RAVES). Circulation 1994; 90: I-125.Google Scholar
  65. 65.
    Colombo A, Nakamura S, Hall P, Maiello L, Blengino S, Martini G. A prospective study of Wiktor coronary stent implantation treated only with antiplatelet therapy. Circulation 1994; 90: I-124.Google Scholar
  66. 66.
    Elias J, Monassier JP, Puel J, Grollier G, Khalife K, Hanssen M, et al. G. Medtronic Wiktor stent implantation without coumadin:Hospital outcome. Circulation 1994; 90: I-124.Google Scholar
  67. 67.
    Hall P, Colombo A, Nakamura S, Maiello L, Blengino S, Ferraro M, et al. A prospective study of Gianturco Roubin stent implantation without subsequent anticoagulation. Circulation 1994; 90: I-124.Google Scholar
  68. 68.
    Aubry P, Royer T, Spaulding C, Lancelin B, Faivre R, Henry M, et al. Coronary stenting without coumadin. Phase II and III, the bail out group. Circulation 1994; 90: I-124.Google Scholar
  69. 69.
    Morice MC. Advances in post-stenting medication protocol. J Intery Cardiol 1995; 7: 32A–35A.Google Scholar
  70. 70.
    Morice MC, Bourdonnec C, Lefevre T, Blanchard D, Monassier JP, Lienhart Y, et al. Coronary stenting without coumadin. Phase III. Circulation 1994; 90: I-125.Google Scholar
  71. 71.
    Morice MC, Zemour G, Benveniste E, Biron Y, Bourdonnec C, Faivre R, et al. Intracoronary stenting without coumadin. One month results of a French multicenter study. Cathet Cardiovasc Diagn 1995; 35: 1–7.PubMedCrossRefGoogle Scholar
  72. 72.
    Lablanche JM, Grollier G, Danchin N, Bonnet JL, Van Belle E, McFadden E, et al. Full antiplatelet therapy without anticoagulation after coronary stenting. J Am Coll Cardiol 1995; 25: 181A.Google Scholar
  73. 73.
    Wong C, Popma J, Chuang Y, Mintz G, Satler L, Kent K, et al. Economic impact of reduced anticoagulation after saphenous vein graft stent placement. J Am Coll Cardiol 1995; 25: 80A.Google Scholar
  74. 74.
    Fajadet J, Jordan C, Carvalho H, Cassagneau B, Robert G, Laurent JP, et al. Percutaneous transradial coronary stenting without coumadin can reduce vascular access complications and hospital stay. J Am Coll Cardiol 1995; 25: 182A.Google Scholar
  75. 75.
    Blasini R, Mudra H, Schuhlen H, Regar E, Klauss V, Zitzmann E, et al. Intravascular ultrasound guided optimized emergency coronary Palmaz-Schatz stent placement without post-procedural systemic anticoagulation. J Am Coll Cardiol 1995: 25: 197A.Google Scholar
  76. 76.
    Reifart N, Haase J, Vandormael M, Macaya C, Geschwind H, Vallbracht C, et al. for the GRACE Investogators. Gianturco-Roubin Stent Acute Closure Evaluation (GRACE): thirty-day outcomes compared to drug regimen. Circulation 1995; 92: I-409.Google Scholar
  77. 77.
    Hall P, Colombo A, Itoh A, Maiello L, Blengino S, Finci L, et al. Gianturco-Roubin stent implantation in small vessels without anti-coagulation. Circulation 1995; 92: I-795.Google Scholar
  78. 78.
    Haase H, Reifart N, Baier T, Hofmann M, Klopper JW, Silberer E, et al. Bail-out stenting (PalmazSchatz) without anti-coagulation. Circulation 1995; 92: I-795.Google Scholar
  79. 79.
    Goods C, Al-Shaibi K, Iyer S, Dean LS, Yadav S, Nugus B, et al. Flexible coil coronary stenting without anti-coagulation or intravascular ultrasound: a prospective observational study. Circulation 1995; 92: I-795.Google Scholar
  80. 80.
    Belli G, Whitlow P, Gross L, Franco I, Raymond R, DeFranco A, et al. Intracoronary stenting without oral anti-coagulation: the Cleveland Clinic Registry. Circulation 1995; 92: I-796.Google Scholar
  81. 81.
    Morice M, Breton C, Bunouf P, Cattan S, Eltchaninoff H, Henry M, et al. Coronary stenting without anti-coagulant, without intravascular ultrasound. Results of the French Registry. Circulation 1995; 92: I-796.Google Scholar
  82. 82.
    Carvalho H, Fajadet J, Jordan C, Cassagneau B, Robert G, Marco J, et al. A lower rate of complications after Gianturco-Roubin coronary stenting using a new anti-platelet and anti-coagulant protocol. Circulation 1994; 90: I-125.Google Scholar
  83. 83.
    Hall P, Nakamura S, Maiello L, Itoh A, Blengino S, Martini G, et al. A randomized comparison of combined ticlopidine and aspirin therapy versus aspirin therapy alone after successful intravascular ultrasound guided stent implantation. Circulation 1996; 93: 215–222.PubMedCrossRefGoogle Scholar
  84. 84.
    Lefevre T, Morice M, Labrunie B, Chabrillat Y, Guerin Y, Pilliere R, et al. Coronary stenting in elderly patients. Results from the stent without coumadin French Registry. J Am Coll Cardiol 1996; 27: 252A.Google Scholar
  85. 85.
    Morice M, Valelx B, Marco J, Goy JJ, Commeau P, Reifart N, et al. Preliminary results of the MUST trial, major clinical events during the first month. J Am Coll Cardiol 1996; 27: 137A.Google Scholar
  86. 86.
    Goods C, Al-Shaibi K, Negus B, Liu M, Yadav S, Jain S, et al. Is ticlopidine a necessary component of anti-platelet regimens following coronary artery stenting. J Am Coll Cardiol 1996; 27: 137A.Google Scholar
  87. 87.
    Marco J, Fajadt J, Brunel P, et al. First use of the second generation Gianturco-Roubin stent without coumadin. Am J Cardiol 1996 in press.Google Scholar
  88. 88.
    Elias J, Monassier J, Carrie D, Khalife K, Grollier G, Labbe T, et al. Final results of the phase II, III, IV, and V of Medtronic Wiktor stent implantation without coumadin. J Am Coll Cardiol 1996; 27: 15A.Google Scholar
  89. 89.
    Walter H, Neumann FJ, Richardt G, Alt E, Schmitt C, Blasini R, et al. Antiplatelet vs. anticoagulation treatment after intracoronary Palmaz-Schatz stent placement in acute myocardial infarction. A prospective randomized trial. J Am Coll Cardiol 1996; 27: 279A.Google Scholar
  90. 90.
    Moussa I, DiMario C, Reimers B, Akiyama T, Tobis J, Colombo A. Subacute stent thrombosis in the era of intravascular ultrasound guided coronary stenting without anti-coagulation: frequency, predictors, and clinical outcome. J Am Coll Cardiol 1997; 29: 6–12.PubMedCrossRefGoogle Scholar
  91. 91.
    Serruys PW, Emanuelsson H, van der Giessen W, Lunn AC, Kiemeney F, Macaya C, et al. Heparin coated Palmaz-Schatz stents in human coronary arteries: early outcome of the Benestent II pilot trial. Circulation 1996; 93: 412–422.PubMedCrossRefGoogle Scholar
  92. 92.
    Curier JW, Faxon DP. Restenosis after PTCA: have we been aiming at the wrong target ? J Am Coll Cardiol 1995; 25: 516–520.CrossRefGoogle Scholar
  93. 93.
    O’Brien ER, Alpers CE, Stewart DK, Ferguson M, Tran N, Gordon D, et al. Proliferation in primary and restenotic coronary atherectomy tissue: implications for anti-proliferative therapy. Circ Res 1993; 73: 223–231.PubMedCrossRefGoogle Scholar
  94. 94.
    Mintz GS, Popma JJ, Pichard AD, Kent KM, Satler LF, Popma JJ, et al. Intravascular ultrasound predictors of restenosis after percutaneous transluminal coronary angioplasty. J Am Coll Cardiol 1996; 27: 1678–1687.PubMedCrossRefGoogle Scholar
  95. 95.
    Dussaillant GR, Mintz GS, Pichard AD, Kent KM, Satler LF, Popma JJ, et al. Small stent size and intimal hyperplasia contribute to restenosis: a volumetric intravascular ultrasound analysis. J Am Coll Cardiol 1995; 26: 720–724.PubMedCrossRefGoogle Scholar
  96. 96.
    Teirstein PS, Massullo V, Jani S, Popma JJ, Mintz GS, Russo RJ, et al. Catheter based radiotherapy to inhibit restenosis after coronary stenting. N Engl J Med 1997; 336: 1697.PubMedCrossRefGoogle Scholar
  97. 97.
    Gibson M, Marble S, Rizzo M, Ryan K, McLean C, Sparano A, et al. Pooled analysis of primary stenting in acute MI in 1,357 patients. Circulation 1997; 96: I-340.Google Scholar
  98. 98.
    Stone GW, Brodie BR, Griffin JJ, Morice MC, Costantini C, St Goar FG, et al. for the Primary Angioplasty and Myocardial Infarction (PAMI) Stent Pilot Trial Investigators. Prospective, multicenter study of the safety and feasibility of primary stenting in acute myocardial infarction: in-hospital and 30 day results of the PAMI Stent Pilot Trial. J Am Coll Cardiol 1998; 31: 23–30.PubMedCrossRefGoogle Scholar
  99. 99.
    The TIMI Study Group. The thrombolysis in myocardial infarction (TIMI) trial. N Engl J Med 1985; 31: 932–936.CrossRefGoogle Scholar
  100. 100.
    Azar AJ, Detre K, Goldberg S, Kiemeneij F, Leon MB, Serruys PW. A meta-analysis on the clinical and angiographic outcomes of stents versus PTCA in the different coronary vessel sizes in the BenestentI and the STRESS-I/II trials. Circulation 1995; 92: I-475.Google Scholar
  101. 101.
    Bairn DS, Levine MJ, Leon MB, Levine S, Ellis SG, Schatz RA, for the US Palmaz-Schatz Stent Investigators: Management of restenosis within Palmaz-Schatz coronary stent (the US Multicenter Experience). The US Palmaz-Schatz Stent Investigators. Am J Cardiol 1993; 71: 364–366.CrossRefGoogle Scholar
  102. 102.
    Alfonso F, Rodriguez P, Phillips P, Goicolea J, Hernandez R, Perez-Vizcayano MJ, et al. Clinical and angiographic implications of coronary stenting in thrombus containing lesions. J Am Coll Cardiol 1997; 29: 725–733.PubMedCrossRefGoogle Scholar
  103. 103.
    Rigel DF, Olson RW, Lappe RW. Comparison of hirudin and heparin as adjuncts to streptokinase thrombolysis in a canine model of coronary thrombolysis. Circulation 1993; 72: 1091–1102.CrossRefGoogle Scholar
  104. 104.
    Cannon CP, McCabe CH, Henry TD, Schweiger MJ, Gibson RS, Mueller HS, et al. A pilot trial of recombinant desulfatohirudin with heparin in conjunction with tissue type plasminogen activator and aspirin for acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 5 Trial. J Am Coll Cardiol 1994; 23: 993–1003.PubMedCrossRefGoogle Scholar
  105. 105.
    Antman EM, for the TIMI 9A Investigators. Hirudin in acute myocardial infarction: Safety report from the Thrombolysis and Thrombin inhibition in Myocardial Infarction (TIMI) 9A trial. Circulation 1994; 90: 1624–1630.PubMedCrossRefGoogle Scholar
  106. 106.
    The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIA Investigators. A randomized trial of intravenous heparin vs recombinant hirudin for acute coronary syndromes. Circulation 1994; 90: 1631–1637.CrossRefGoogle Scholar
  107. 107.
    Ferguson JJ. Meeting highlights: AHA 68th Scientific Sessions, “TIMI 9B”: Heparin vs hirudin as adjunctive therapy for thrombolysis in acute myocardial infarction. Circulation 1996; 93: 843.PubMedCrossRefGoogle Scholar
  108. 108.
    Armstrong P, Granger C, Califf R, Van der Werf F, Topol E. GUSTO 2B trial. American College of Cardiology, Orlando, FL, 1996.Google Scholar
  109. 109.
    Gibson CM, Rizzo MJ, McLean C, Dotani I, Goel M, Ryan K, et al. for the RESTORE Investigators. The TIMI Frame Count and Restenosis: faster is better. J Am Coll Cardiol 1997; 29: 201A.Google Scholar

Copyright information

© Springer Science+Business Media New York 1999

Authors and Affiliations

  • Mukesh Goel
  • Anthony M. Sparano
  • John Moynihan
  • Michael Kelley
  • C. Michael Gibson

There are no affiliations available

Personalised recommendations